Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.5
4.2
Journals
Toxins
Special Issues
Uremic Toxins and Drugs
share announcement

Uremic Toxins and Drugs

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Uremic Toxins".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 8896

Special Issue Editors

Prof. Dr. Sophie Liabeuf

E-Mail Website
Guest Editor
Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France and EA7517 Unit— MP3CV, UPJV University, Amiens, France
Interests: uremic toxins; pharmaco-epidemiology, cardiovascular; vascular calcification
Special Issues, Collections and Topics in MDPI journals
Dr. Youssef Bennis

E-Mail Website
Guest Editor
Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France and EA7517 Unit— MP3CV, UPJV University, Amiens, France
Interests: uremic toxins; cardiovascular calcifications; inflammation; pharmacokinetics

Special Issue Information

Dear Colleagues,

Patients with chronic kidney disease (CKD) are at a high risk of morbidity and mortality. Kidney function decline in CKD is associated with the accumulation of compounds which under normal conditions are cleared by healthy kidneys. If they interfere with biological/biochemical functions, these solutes are called uremic toxins. Uremic toxins have been classified into three classes depending on molecular weight and protein binding:  small water-soluble molecules, middle molecules, and protein bound molecules. Several groups of authors have shown that high serum levels of a variety of uremic toxins are associated with mortality and cardiovascular and renal events. Thus, these toxins are potential therapeutic targets. Research on pharmacological treatment to reduce uremic toxins levels or prevent their deleterious effects are crucial.

In addition to direct tissue toxicity, their negative impact could also result from changes in the pharmacokinetic/pharmacodynamic activity of numerous drugs. Recent data have also suggested a potential impact of drugs on levels of uremic toxins.

The focus of this Special Issue of Toxins will include original research articles and reviews on uremic toxins and drugs that could present two different aspects: i) pharmacological tools to reduce uremic toxins levels or prevent their deleterious effects and ii) potential interactions between uremic toxins and drugs.

Prof. Dr. Sophie Liabeuf
Dr. Youssef Bennis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uremic toxins
  • drugs
  • therapeutic target
  • interaction
  • AhR
  • OATs
  • gut microbiota
  • inflammation
  • oxidative stress
  • cell senescence
  • pharmacokinetics

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 541 KiB  
Article
The Prescription of Drugs That Inhibit Organic Anion Transporters 1 or 3 Is Associated with the Plasma Accumulation of Uremic Toxins in Kidney Transplant Recipients
by Camille André, Touria Mernissi, Gabriel Choukroun, Youssef Bennis, Saïd Kamel, Sophie Liabeuf and Sandra Bodeau
Toxins 2022, 14(1), 15; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins14010015 - 25 Dec 2021
Cited by 4 | Viewed by 2478
Abstract
The renal elimination of uremic toxins (UTs) can be potentially altered by drugs that inhibit organic anion transporters 1/3 (OAT1/OAT3). The objective of the present study was to determine whether the prescription of at least one OAT1/OAT3 inhibitor was associated with the plasma [...] Read more.
The renal elimination of uremic toxins (UTs) can be potentially altered by drugs that inhibit organic anion transporters 1/3 (OAT1/OAT3). The objective of the present study was to determine whether the prescription of at least one OAT1/OAT3 inhibitor was associated with the plasma accumulation of certain UTs in kidney transplant recipients. We included 403 kidney transplant recipients. For each patient, we recorded all prescription drugs known to inhibit OAT1/OAT3. Plasma levels of four UTs (trimethylamine N-oxide (TMAO), indole acetic acid (IAA), para-cresylsulfate (pCS), and indoxylsulfate (IxS) were assayed using liquid chromatography-tandem mass spectrometry. Plasma UT levels were significantly higher among patients prescribed at least one OAT inhibitor (n = 311) than among patients not prescribed any OAT inhibitors (n = 92). Multivariate analysis revealed that after adjustment for age, estimated glomerular filtration rate (eGFR), plasma level of albumin and time since transplantation, prescription of an OAT1/OAT3 inhibitor was independently associated with the plasma accumulation of pCS (adjusted odds ratio (95% confidence interval): 2.11 (1.26; 3.61]). Our results emphasize the importance of understanding the interactions between drugs and UTs and those involving UT transporters in particular. Full article
(This article belongs to the Special Issue Uremic Toxins and Drugs)
►▼ Show Figures

Figure 1

9 pages, 830 KiB  
Article
The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients
by Kenshiro Hirata, Tokunori Ikeda, Hiroshi Watanabe, Toru Maruyama, Motoko Tanaka, Victor Tuan Giam Chuang, Yuji Uchida, Keiki Sakurama, Koji Nishi, Keishi Yamasaki and Masaki Otagiri
Toxins 2021, 13(11), 811; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13110811 - 18 Nov 2021
Cited by 4 | Viewed by 2199
Abstract
The binding of drugs to plasma protein is frequently altered in certain types of renal diseases. We recently reported on the effects of oxidation and uremic toxins on the binding of aripiprazole (ARP) to human serum albumin. In our continuing investigations, we examined [...] Read more.
The binding of drugs to plasma protein is frequently altered in certain types of renal diseases. We recently reported on the effects of oxidation and uremic toxins on the binding of aripiprazole (ARP) to human serum albumin. In our continuing investigations, we examined the binding of ARP to plasma pooled from patients with chronic renal dysfunction. We examined the issue of the molecular basis for which factors affect the changes in drug binding that accompany renal failure. The study was based on the statistical relationships between ARP albumin binding and biochemical parameters such as the concentrations of oxidized albumin and uremic toxins. The binding of ARP to plasma from chronic renal patients was significantly lower than healthy volunteers. A rational relationship between the ARP binding rate and the concentration of toxins, including indoxyl sulphate (IS) and p-cresyl sulphate (PCS), was found, particularly for IS. Moreover, multiple regression analyses that involved taking other parameters such as PCS or oxidized albumin ratio to IS into account supports the above hypothesis. In conclusion, the limited data reported in this present study indicates that monitoring IS in the blood is a very important determinant in the dosage plan for the administration of site II drugs such as ARP, if the efficacy of the drug in renal disease is to be considered. Full article
(This article belongs to the Special Issue Uremic Toxins and Drugs)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1152 KiB  
Review
The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction
by Regiane Stafim da Cunha, Carolina Amaral Bueno Azevedo, Carlos Alexandre Falconi, Fernanda Fogaça Ruiz, Sophie Liabeuf, Marcela Sorelli Carneiro-Ramos and Andréa Emilia Marques Stinghen
Toxins 2022, 14(3), 177; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins14030177 - 26 Feb 2022
Cited by 14 | Viewed by 3730
Abstract
Uremic toxins are a heterogeneous group of molecules that accumulate in the body due to the progression of chronic kidney disease (CKD). These toxins are associated with kidney dysfunction and the development of comorbidities in patients with CKD, being only partially eliminated by [...] Read more.
Uremic toxins are a heterogeneous group of molecules that accumulate in the body due to the progression of chronic kidney disease (CKD). These toxins are associated with kidney dysfunction and the development of comorbidities in patients with CKD, being only partially eliminated by dialysis therapies. Importantly, drugs used in clinical treatments may affect the levels of uremic toxins, their tissue disposition, and even their elimination through the interaction of both with proteins such as albumin and cell membrane transporters. In this context, protein-bound uremic toxins (PBUTs) are highlighted for their high affinity for albumin, the most abundant serum protein with multiple binding sites and an ability to interact with drugs. Membrane transporters mediate the cellular influx and efflux of various uremic toxins, which may also compete with drugs as substrates, and both may alter transporter activity or expression. Therefore, this review explores the interaction mechanisms between uremic toxins and albumin, as well as membrane transporters, considering their potential relationship with drugs used in clinical practice. Full article
(This article belongs to the Special Issue Uremic Toxins and Drugs)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop